Criteria for FM and SpA: state of the art {#s1}
=========================================

From psychogenic rheumatism to fibromyalgia syndrome
----------------------------------------------------

The term FM was initially proposed in 1975 ([@B9]) to replace the old term fibrositis and was officially approved by the American College of Rheumatology (ACR) Committee while developing the 1990 classification criteria ([@B10]). The evidence that widespread pain was a key symptom complained of patients and that trigger points were the most powerful discriminator between patients and controls, led to the inclusion of these two observations as classification criteria for FM ([@B10]). Compared to the first set of criteria, that were highly specific but poorly sensitive and therefore missed a consistent proportion of FM patients, the ACR 1990 criteria ensured a higher sensitivity. However, after 20 years and many debates on the same matter, it became evident that the 1990 criteria had similar major pitfalls. The lack of proper implementation of trigger point assessment in daily practice, mainly in primary care where most of FM diagnosis occur, led to symptom-based rather than criteria-based identification of patients. Furthermore, the lack of other key manifestations within the FM-related clinical spectrum, such as fatigue and cognitive symptoms, was a major argument underpinning the need of a new set of criteria. The Manchester criteria were published in 1996 and used a widespread pain diagram to establish the diagnosis, but still did not include other relevant domains in the clinical spectrum of FM ([@B11]). In 2003, the combination of a Regional Pain Scale (RPS) score, combined with a fatigue score on a visual analog scale (VAS), was proposed (the so-called "Survey criteria") ([@B12], [@B13]) and a few years later, an ACR committee was convened to build the ACR 2010 preliminary diagnostic criteria. In these criteria, the widespread pain index (WPI) and the symptom severity (SS) scale score were included to encompass the wide clinical picture of FM. Using the 2010 criteria, patients may be diagnosed with FM if they fulfill specific cut-offs, both for the WPI and the SS concomitantly to symptoms lasting for ≥3 months and no other condition that could explain their pain ([@B14]). In 2011, a modified version of the 2010 criteria was proposed that relied on self-reported pain and a simplified self-reported version of somatic symptoms ([@B15]). Finally, criteria combining the 2010 and the modified 2011 set were released in 2016 ([@B16]). In parallel to the release of the 2010 diagnostic criteria, the French Rheumatic Pain Study Group (Cercled\'Etude de la Douleur en Rhumatologie, CEDR) developed and validated a patient self-completed questionnaire for the detection of FM in patients with chronic widespread pain: the Fibromyalgia Rapid Screening Tool (FiRST) ([@B17]). A previous screening tool, to be employed in epidemiological studies, the London Fibromyalgia Epidemiology Study Screening Questionnaire (LFESSQ) was developed in 1999 ([@B18]) while the FiRST, owing to its briefness and good performance, was tailored to be a companion for clinicians in daily practice. FM should no longer be viewed merely as the physical manifestation of psychological distress but instead as a central and peripheral pain hypersensitivity syndrome that could be secondary, in some cases, to the chronic inflammation. On this basis, FM should be diagnosed based on positive criteria instead of by elimination and should be managed in its own right in patients with other comorbidities, including rheumatic diseases.

The kaleidoscope of criteria for spondyloarthritis
--------------------------------------------------

Several sets of classification criteria have been proposed over the last decades not only to ensure the correct identification of patients displaying different clinical features, but also to acknowledge and incorporate the evolution of imaging techniques and the compelling need to reduce the diagnostic delay ([@B19]). The human leukocyte antigens (HLA) B27 gene, the natural function of which is to present intracellular peptides to cytotoxic T lymphocytes, is strongly associated with SpA ([@B20]). The prevalence of HLA-B27 in the general population ranges from around 2 to 6% ([@B21], [@B22]), while it reaches 94% in AS ([@B20]). However, in other phenotypes of the SpA spectrum, HLA-B27 can be detected in lower proportions ranging from 30 to 75% ([@B20]). Inflammatory back pain (IBP) is a hallmark of axial SpA (axSpA) and its features were defined in several sets of criteria ([@B23]--[@B26]). The insidious onset of back pain lasting for at least 3 months, associated with morning stiffness improving with exercise in an individual aged 40--45 years or below, represented the basis for subsequent criteria for axSpA including the Assessment of Spondyloarthritis International Society (ASAS) 2004 ([@B24]), the Berlin 2006 ([@B25]) and the ASAS 2009 ([@B26]). In parallel, Calin\'s definition was also incorporated in the framework of the 1966 New York criteria for ankylosing spondylitis (AS) ([@B27]) which modified version was released in 1984 ([@B28]). The first set of criteria encompassing the entire clinical spectrum of SpA was developed by Amor in 1990 ([@B29]), followed by the European Spondylarthropathy Study Group (ESSG) criteria of 1991 ([@B30]) and the ASAS ([@B24], [@B26]). With regard to PsA, the definition of Moll and Wright in 1973, evolved and culminated in the latest set of criteria which is currently used, was released in 2006 by the classification of psoriatic arthritis (CASPAR) study group ([@B31]). An open question fuelling the debate in the scientific community is the one relating to non-radiographic axial (nr-ax)-SpA ([@B32]). The ASAS 2009 criteria include a milestone in this regard, as the item "sacroiliitis on imaging" now includes not only definitive radiographic changes according to modified New York criteria but also acute bone marrow oedema on magnetic resonance imaging (MRI), highly suggestive of SpA. In this regard, the ASAS-OMERACT MRI group defined active sacroiliitis on MRI based on the kind (bone marrow oedema/osteitis, synovitis of sacroiliac joints, enthesitis or capsulitis) and extension of lesions ([@B33]).

The performance of FM criteria in patients with concomitant SpA and vice-versa {#s2}
==============================================================================

The complexity of SpA and FM clinical pictures, along with the different classification criteria available, account for the difficulty to compare studies exploring FM prevalence in SpA and vice-versa. A recent systematic literature review and meta-analysis discussed 10 studies assessing FM prevalence in SpA using the ACR 1990 and/or 2010 classification as inclusion criteria ([@B7]) but, as summarized in Table [1](#T1){ref-type="table"}, the actual number of available studies is higher. It is interesting to note that the large majority of studies, many of which were published after the release of the 2010 ACR criteria, still assessed FM with the 1990 ACR criteria ([@B6], [@B34]--[@B40], [@B42], [@B44], [@B50]), while only four used the 2010 ACR criteria ([@B41], [@B47], [@B49], [@B52]) and only two used both criteria ([@B45], [@B48]). Four studies explored the FiRST tool either alone ([@B43]) or in comparison to the ACR 1990 ([@B46], [@B53]) or ACR 2010 ([@B51]) criteria. With regard to AS, data resulting from over one thousand patients demonstrate a prevalence of FM ranging between 6.4 and 25% based on the ACR 1990 criteria ([@B6], [@B34]--[@B36], [@B40], [@B46], [@B50]). The only study using the ACR 2010 criteria, enrolling 211 AS patients, observed a prevalence of 12.7% ([@B41]), while the study using the FiRST tool reported a prevalence of 22.3% of FM in AS (compared to a prevalence of 6.4% with the ACR 1990 criteria) ([@B46]). In studies assessing FM in overall axSpA according to the ASAS criteria without prior FM diagnosis, the prevalence was 13.2% with the ACR 1990 criteria ([@B48], [@B53]), between 17.2 and 60% with the ACR 2010 criteria ([@B41], [@B51]) and 36% with the FiRST tool ([@B51]).

###### 

Studies evaluating the prevalence of fibromyalgia in patients with spondyloarthritis.

  **References**                 **Disease**            **N°pts**      **SpA criteria**                                **FM (1990 criteria)**                  **FM (2010 criteria)**   **FM (FiRST)**
  ------------------------------ ---------------------- -------------- ----------------------------------------------- --------------------------------------- ------------------------ ----------------------
  Aloush et al. ([@B34])         AS                     36             Mod. New York                                   25%                                     NA                       NA
  Almodóvar et al. ([@B35])      AS                     462            Mod. New York                                   4.1%                                    NA                       NA
  Azevedo et al. ([@B36])        AS                     71             Mod. New York                                   15%                                     NA                       NA
  Husted et al. ([@B37])         PsA                    390            CASPAR                                          27.2%                                   NA                       NA
  Roussou and Ciurtin ([@B38])   SpA PsA                60 20          Calin and Berlin CASPAR                         30% TeP criterion 50% TeP criterion     NA                       NA
  Husted et al. ([@B39])         PsA                    631            CASPAR                                          22%                                     NA                       NA
  Demirdal et al. ([@B40])       AS                     71             Mod. New York                                   16.9%                                   NA                       NA
  Salaffi et al. ([@B41])        AS axSpA               211 191        Mod. New York ASAS                              NA                                      12.7% 17.2%              NA
  Haliloglu et al. ([@B6])       AS                     119            New York                                        12.6%                                   NA                       NA
  Graceffa et al. ([@B42])       PsA                    74             CASPAR                                          16%                                     NA                       NA
  Bello et al. ([@B43])          SpA                    185            ASAS                                            NA                                      NA                       20.5%
  Wach et al. ([@B44])           axSpA pSpA             81 22          Amor and ASAS ESSG and ASAS                     14.8% 27.3%                             NA                       NA
  Brikman et al. ([@B45])        PsA                    73             CASPAR                                          8.2% TeP criterion 1.4% both criteria   16.4%                    NA
  Fan et al. ([@B46])            AS nr-axSpA pSpA PsA   126 64 52      New York ASAS ASAS CASPAR                       6.4% 23.9% NA 9.6%                      NA                       22.3% 36.4% NA 22.9%
  Macfarlane et al. ([@B47])     SpA                    1,041 398 65   Mod. New York ASAS radiological ASAS clinical   NA                                      19.7% 25.2% 9.5          NA
  Baraliakos et al. ([@B48])     axSpA                  200            ASAS                                            13.5%                                   24%                      NA
  Di Carlo et al. ([@B49])       PsA                    144            CASPAR                                          NA                                      18.8%                    NA
  Fan et al. ([@B50])            AS PsA pSpA nr-axSpA   137 59 38 64   Mod. New York CASPAR ASAS ASAS                  6.4% 9.6% 5.3% 23.9%                    NA                       NA
  Dantu et al. ([@B51])          axSpA                  25             ASAS                                            NA                                      60%                      36%
  Dantu et al. ([@B52])          axSpA                  51             ASAS                                            NA                                      47%                      NA
  Moltó et al. ([@B53])          axSpA                  441 85         ASAS Any except ASAS                            13.2 32.9                               NA                       38% 41.2%

*N°, number; Pts, patients; FM, fibromyalgia; AS, ankylosing spondilytis; SpA, spondyloarthritis; ax, axial; p, peripheral; PsA, psoriatic arthritis; nr, non-radiographic, TeP, tender points; NA, not assessed; ASAS, Assessment of Spondyloarthritis International Society; CASPAR, classification of psoriatic arthritis; ESSG, European Spondylarthropathy Study Group; FiRST, Fibromyalgia Rapid Screening Tool*.

The study considering nr-axSpA as a separate entity reported a prevalence of FM of 23.9% and 36.4% using the ACR 1990 criteria and the FiRST tool, respectively ([@B46]). In peripheral (pSpA) according to either ESSG or ASAS criteria the prevalence of FM was assessed only with the ACR 1990 criteria and resulted between 5.3 and 27.3% ([@B44], [@B50]). All available studies on PsA used the CASPAR criteria and reported a prevalence of FM ranging from 1.4 to 37.3% with the ACR 1990 criteria ([@B37], [@B39], [@B42], [@B45], [@B46]) and from 16.4 to 18.8% with the ACR 2010 criteria ([@B45], [@B49]). The main observation arising from the above mentioned studies is that, despite the pitfalls pointed out about the 1990 ACR criteria (the lack of their adequate implementation in clinical practice), and most importantly, the availability of a new and more recent set of criteria, these are still the most commonly employed for research purposes. It is therefore difficult to translate these results into clinical practice and, most importantly, to fully understand similarities and differences not only among the two sets of ACR criteria but also with recent tools, such as the FiRST.

When looking at how many patients with FM would fulfill SpA criteria, the number of related publications is much lower and, as a consequence, the results even less clear (Table [2](#T2){ref-type="table"}). In one study conducted in patients diagnosed with FM according to the ACR 1990 criteria, only 10% fulfilled the ASAS criteria ([@B56]). Of these, 80% fulfilled the ASAS criteria based on MRI findings diagnostic of sacroiliitis and the remaining 20% fulfilled the criteria based on the presence of HLA--B27 and SpA features. The study by Rousseau et al explored how many patients with FM would fulfill three sets of clinical criteria for SpA according to the ACR 2010 criteria. Over 60% of FM patients fulfilled either the Calin or the Berlin criteria, while 23% fulfilled the clinical arm of the ASAS criteria ([@B55]). No data are available regarding the evidence of radiographic or MRI sacroiliitis. In another cohort of FM patients diagnosed according to the ACR 2010 criteria, only 2% of them fulfilled the ASAS criteria ([@B48]). Interestingly, such low prevalence could be explained by the prospective nature of the study in a real-life population of patients with axSpA. When assessing the subgroup of FM patients with HLA-B27 available, this proportion raised to 5% but still remained very much below the 23% observed by Roussou and Georgiou ([@B55]). Finally, when considering the Amor or ESSG criteria, they were fulfilled by almost half of FM patients (diagnosed with the ACR 1990 and 2010 criteria) ([@B54]). Of interest, the prevalence of radiographic sacroiliitis grade 2 or higher was similar in patients\' subgroups fulfilling either ACR 1990, ACR 2010 or both set of criteria and was around 30%. Of those with sacroiliitis grade 1 or 2 at conventional radiograms, only 4% displayed sacroiliitis at MRI. These findings open an intriguing scenario for further discussion which also includes the relevance of imaging in shedding some light on the actual co-existence, with consequent therapeutic implications, of FM and SpA. Moreover, it should be kept into account that fatigue can be detected in up to half SpA patients ([@B57]). This can be due not only to disease activity but notably also to psychogenic factors, especially depression. Therefore, it is imperative to rule out whether we are dealing with SpA-related fatigue, psychogenic fatigue or an actual diagnosis of FM. Unfortunately, such distinction is not easy, therefore, the question remains on whether it came first the chicken or the egg.

###### 

Studies evaluating the prevalence of spondyloarthritis in patients with fibromyalgia.

  **References**                  **N°pts**   **Criterion for FM diagnosis**       **SpA prevalence**   **nr-axSpA**   **Fulfilled criteria**
  ------------------------------- ----------- ------------------------------------ -------------------- -------------- ------------------------
  Kaşkari et al. ([@B54])         41 15       ACR 1990 or 2010 ACR 1990 and 2010   31.7% 46.6%          NA             Amor and ESSG
  Baraliakos et al. ([@B48])      100         ACR 1990 and ACR 2010                2%                   0              ASAS
  Roussou and Georgiou ([@B55])   95          ACR 2010                             62% 69% 23%          NA             Calin Berlin ASAS
  Ablin et al. ([@B56])           99          ACR 1990                             10%                  2              ASAS

*N°, number; Pts, patients; FM, fibromyalgia; ACR, American College of Rheumatology; SpA, spondyloarthritis, nr-ax, non-radiographic axial; NA, not assessed; ASAS, Assessment of Spondyloarthritis International Society; ESSG, European Spondylarthropathy Study Group*.

Imaging to differentiate SpA from FM {#s3}
====================================

The observation that FM patients may fulfill SpA criteria and the need to differentiate active SpA features from FM for appropriate therapeutic management, point out the importance to complement clinical assessment with imaging techniques. With regard to IBP, radiographic sacroiliitis has long been a hallmark of the classification of AS, within the axSpA spectrum ([@B58]). However, this may not be present in early phases of the disease and some patients may never develop such major structural damage, as discussed above. In this scenario, and according to the ASAS 2009 criteria, the evaluation of sacroiliac joints through MRI is therefore crucial. A still open question is whether the ASAS classification criteria may lead to overinterpretation and misclassification, which in consequence, may induce overtreatment of patients with chronic back pain and FM, who may just show minor MRI changes or a positive HLA-B27 finding ([@B48]). An even more challenging scenario is SpA presenting as polyenthesitis without axial involvement and here the role of imaging is of utmost importance. Enthesitis, defined as inflammation of tendon, ligament, and joint capsule insertions to the bones, is a hallmark of SpA ([@B59]). Entheseal regions are well-innervated, but are completely avascular at attachment sites and have a low density of blood vessels in the adjacent ligaments and tendons ([@B60]). On this basis, although pain, tenderness and stiffness are its main clinical manifestations, in most cases enthesitis occurs without visible signs of clinical inflammation and without increased acute phase reactants ([@B61]). Moreover, many entheses are not clinically accessible, located deep inside the human body. Often, clinical examination of enthesitis is inconclusive and the decision to initiate or adapt therapy is difficult. Finally, these entheseal SpA may be extremely difficult to distinguish from FM. The enthesitis score used in SpA has been criticized owing to its lack of correlation with objective measures of enthesitis, such as MRI, and because it overlaps with the FM tender point score ([@B38], [@B62]). From these anatomical and clinical considerations, in order to differentiate SpA-related enthesitis and FM, we require sensitive and advanced imaging techniques. Radiography only detects changes at a relatively late stage of disease, such as periosteal bony apposition or bony erosions, and is inferior to MRI in the evaluation of the disease extent and severity ([@B63], [@B64]). Scintigraphy has been widely used in the past; however, due to its lack of specificity it has been replaced by MRI and ultrasound (US) ([@B65], [@B66]). Despite providing interesting preliminary results ([@B67], [@B68]), positron emission tomography (PET) does seem neither specific nor able to offer the same excellent spatial resolution as MRI, requiring further research in this field.

Musculoskeletal US with power Doppler (PDUS) is a valid and reliable means of evaluating SpA enthesitis ([@B69]). On this basis, PDUS may provide further helpful information for distinguishing enthesitis and FM. However, it is important to highlight that age-related changes may occur at normal entheses, particularly in patients with high body mass index (BMI), so it is possible that patients with FM may show some degree of entheseal change. Some studies suggest that abnormal vascularity at the entheseal level characterize SpA patients, even if asymptomatic, with respect to healthy controls ([@B70]--[@B72]), although the presence of Doppler positivity seems to have a low sensitivity (36%) ([@B72]). The range of enthesophytes, a chronic entheseal change, in healthy controls overlapped the ranges of patient with psoriasis and PsA ([@B72]). However, enthesophytes are not specific to enthesitis and may be related to mechanical forces. In a pilot study comparing PDUS-revealed entheseal involvement in patients with PsA and patients with FM, Marchesoni and colleagues concluded that PDUS assessment of peripheral entheses appears to be able to differentiate patients with PsA and patients with FM in terms of number and distribution of involved sites as well as presence of inflammatory changes ([@B73]). However, since the presence of at least 1 lesion at 1 site was quite common in patients with FM (80%), a cut-off point of ≥3 involved sites has been set, providing the greatest discriminating power in patients with PsA, who were the only patients with bony erosions. Inflammatory changes were present in the majority of PsA patients, and the involvement of plantar fascia and Achilles tendon was highly specific of PsA. Many entheseal sites are not accessible for US scans, and, especially in patients with chronic widespread pain, such as FM, their assessment requires an excessive amount of scanning time. MRI methods could overcome the difficulties in the assessment of deeply located enthesis. On MRI, enthesitis is associated with diffuse perientheseal soft tissue oedema that is more conspicuous than inflammation within the insertion, reflecting the greater vascularity of the peri-entheseal tissues ([@B59]). In this context, adjacent osteitis may be present, due to the consistent vascularity of the bone marrow. In their small prospective study, Godfrin and colleagues used technetium 99 m angioscintigraphy and MRI to assess entheses, focusing on sites where the pain was the most severe or where radionuclide scanning showed increased uptake, and a good agreement between radionuclide scanning and MRI was found ([@B74]). In particular, radionuclide scanning and MRI findings establish that isolated entheseal pain could indicate SpA, while both investigations are normal in patients with FM. In contrast to conventional MRI, which only covers one anatomical area in one scan, whole-body MRI (WB-MRI) allows assessment of all peripheral and axial joints and entheses from "head-to-toe" in one examination ([@B75]). The WB-MRI technique could ensure better assessment of disease extent and activity within one examination and therefore improve the detection of entheseal inflammation ([@B76]), unmasking clinically silent enthesitis ([@B77]), while being less obtrusive for patients. Enthesitis can be detected on WB-MRI with moderate agreement between WB-MRI and clinical examination, and, interestingly, patients had more enthesitis at clinical examination than on WB-MRI, whereas it was the opposite for healthy subjects. This may be explained by the presence of subclinical enthesitis, which may be related to other conditions inducing mechanical stress, such as high BMI or physical overuse ([@B77]). Although all the above progress is promising, WB-MRI technique is still under development and, before widespread clinical use, robust research and clarification concerning entheseal abnormalities found also in healthy subjects are needed ([@B61]). Although enthesitis is considered as the primary pathological process underling SpA, it is still difficult to differentiate whether patients have poly-enthesitis, FM or both, because the physical examination may be similar, and other clinical features, for example the response to NSAIDs, need to be taken into consideration. Furthermore, as mentioned above, the poorly understood pathophysiology of FM and the lack of reliable diagnostic biomarkers further complicate this matter. At present, imaging with PDUS scanning or selected MRI scanning of sites with predominant pain, seem to be the most useful tool to be used in this process. In the future, more advanced and sophisticated imaging techniques, such as PET in combination with CT or MRI, or whole-body MRI may be used for this purpose.

FM impact on SpA outcome measures {#s4}
=================================

Given the considerable coexistence of SpA and FM, another crucial point is the impact of the latter on SpA outcome measures and therefore the implications of therapeutic tailoring ([@B78]). Patients with AS and FM usually report significantly worse disease activity, function, global severity scores, and QoL ([@B47]). The AS-QoL score is higher in patients with SpA and FM (B, C, G) and several studies agree that patients with SpA and FM display also higher Bath ankylosing spondylitis disease activity index (BASDAI) scores ([@B6], [@B34]--[@B36], [@B40], [@B47]) and poorer function scores, as calculated with the Bath Ankylosing Spondylitis Functional Index (BASFI) ([@B34]--[@B36], [@B43]). In this regard, objective measures play a major role in discriminating the inflammatory SpA component of disease activity/damage assessment and minimize the interference of FM clinical features. This is supported by the evidence that the ankylosing spondylitis disease activity score (ASDAS)-C reactive protein (CRP), and to a lesser extent the ASDAS-erythrocyte sedimentation rate (ESR), where acute phase reactants are the item with the highest weight, are better discriminators compared to the BASDAI that only includes 10 mm visual analogic scales to be compiled by the patient ([@B41], [@B44]). Likewise, the Bath Ankylosing Spondylitis Radiology Index (BASRI), including AS-specific radiographic changes, is reduced in patients with comorbid FM and, in this regard, Almodovar and colleagues suggested a BASDAI/BASRI ratio equal or over 1.5 to identify patients at high probability to have FM associated with SpA (positive likelihood ratio of 3.1) ([@B35]). With regard to PsA, the composite psoriatic disease activity index (CPDAI) and the disease activity index for psoriatic arthritis (DAPSA) scores are higher in patients with concomitant FM ([@B45]). This also applies to a recently validated patient reported outcome, the Psoriatic Arthritis Impact of Disease (PsAID). In fact, FM is associated to the final PsAID score in PsA patients further underscoring its impact on SpA patient reported outcomes (PROs) ([@B49]).

When focusing on the involvement of enthesis, the enthesitis score used in SpA has been criticized owing to its lack of correlation with objective measures of enthesitis and overlaps with the FM tender point score ([@B38], [@B62]). In this regard, the Leeds enthesitis index (LEI) is significantly higher in PsA patients with concomitant FM.

Having concurrent FM is associated with a higher likelihood of having received biologic therapy in a study from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) ([@B47]). Bello et al. did not observe any differences with regard to the initiation of biologic treatment, but reported a shorter retention rate of the first biologic after 2 years in patients with SpA and FM compared to those with SpA only ([@B43]).

FM diagnosis could predict a lower probability to achieve minimal disease activity or remission in patients with PsA ([@B42], [@B45]) and for instance the LEI is the only variable not showing a significant reduction over time in patients treated with biologic agents ([@B42], [@B45]). Finally, comorbid FM has a negative impact on response to biologic therapies in axSpA ([@B53]). This does not reflect a real reduced efficacy due to concomitant FM but rather the objective and hard to overcome difficulty of patients to detach FM and SpA symptoms when reporting their assessment of disease activity through PROs. All these observations further support the importance of imaging techniques as companion in the diagnostic process to rule out FM in SpA patients and to outline of treatment strategies in order to avoid overestimation of SpA disease activity and therefore overtreatment.

Concluding remarks {#s5}
==================

FM occurs in a significant proportion of SpA patients increasing the chronic symptom burden, reducing overall function, and worsening QoL. This has a dramatic impact not only on the individual but more in general on society in terms of decreased work productivity. While FM may coexist with SpA, disease activity measures that include subjective elements, such as pain and patient global reports may be overstated, even when more objective measures, such as swollen joint count or CRP suggest the achievement of remission or low disease activity. Therefore, PROs may be less valid and reliable as a true measure of inflammatory disease activity and to be used as a basis for therapeutic decision-making in clinical practice in some patients with long-standing disease, since they may lead to intensification of, or switching immunotherapy when it is not necessarily warranted.

On this basis, the coexistence of FM should be assessed in patients with SpA based on the clinician\'s judgment and the use of validated positive criteria/questionnaires, instead of by elimination criteria, with input from both patient and clinician. In addition, sensitive and advanced imaging techniques should be necessarily implemented to differentiate SpA inflammatory pain from FM pain, therefore establishing the most appropriate treatment approach in partnership with the patient.
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